Rezurock for children
Reading File
Finding Sources
Searching the Web
Rezurock belumosudil pediatric children FDA approval age
Searching PubMed
belumosudil pediatric graft versus host disease
Rezurock (belumosudil) in Children
Approved pediatric age: 12 years and older (not for children under 12).
FDA-approved indication
Rezurock (belumosudil) 200 mg once daily is FDA-approved for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy. It received full FDA approval in July 2021, with Breakthrough Therapy designation and Priority Review, as the first ROCK2 (Rho-associated coiled-coil kinase 2) inhibitor approved for this indication - Goldman-Cecil Medicine, and confirmed by FDA/manufacturer sources.
Mechanism (relevant background)
Belumosudil inhibits ROCK2 signaling, which dampens pro-inflammatory Th17 responses (reducing IL-17/IL-21) and pro-fibrotic pathways (STAT3, MRTF-mediated gene expression), addressing both the inflammatory and fibrotic components of chronic GVHD.
What's NOT established
- Safety and effectiveness in children under 12 have not been established. The manufacturer's label explicitly states this.
- It has not been studied for use outside the cGVHD-after-2-prior-therapies setting in pediatrics.
- No data exist on excretion in breast milk; lactating patients (relevant for adolescent context less so, but noted in labeling) are advised not to breastfeed during and for one week after treatment.
What's happening now for younger children
A newer pediatric trial is actively recruiting to extend evaluation below age 12:
- NCT07116031 - "A Study of Belumosudil in Children" - enrolling participants aged 1 to <18 years, with a Phase 1 cohort specifically for ages 1 to <12 years, to establish dosing and safety data in that younger group. This suggests belumosudil may eventually get approval for children younger than 12, but that is not yet the case.
Clinical evidence base
- Cutler CS, Lee SJ, Arai S, et al. established efficacy of belumosudil for cGVHD after ≥2 prior lines of therapy (cited in Goldman-Cecil Medicine, p. 3527, 3655-3666).
- A 2025 systematic review/meta-analysis (PMID: 41241260) and a 2025-2026 real-world experience report specifically in children and young adults (PMID: 41566004) provide more recent outcomes data, though I have not pulled their full findings - let me know if you want those specific results analyzed in depth.
Bottom line
If a child is under 12, Rezurock is not currently indicated and would be off-label/investigational use - discuss with a pediatric transplant/BMT specialist, and consider whether the child is eligible for the ongoing pediatric trial (NCT07116031). For adolescents 12+, it is an approved option for cGVHD refractory to at least two prior systemic therapies, dosed at 200 mg once daily, same as adults.
This is general medical information, not a substitute for guidance from your child's treating hematologist/oncologist or transplant physician, who can weigh disease severity, prior treatment failures, and drug interactions (belumosudil has many CYP3A-related interactions, including with other kinase inhibitors).
Rezurock weight based dosing
Finding Sources
Searching the Web
Rezurock belumosudil weight-based dosing pediatric 12 to 17 years prescribing information
Reading Web Page
https://clinicaltrials.gov/study/NCT07116031
Rezurock (belumosudil) - Dosing Is NOT Weight-Based
Current FDA-approved dosing is a fixed dose regardless of body weight:
- 200 mg orally once daily - this is the standard dose for both adults and adolescents 12-17 years old
- If needed, it's taken with a strong CYP3A inducer or a proton pump inhibitor, the dose adjusts to 200 mg twice daily (still not weight-based - it's a drug-interaction adjustment, not a weight calculation)
There is no mg/kg or body-surface-area formula in the current prescribing information for the approved 12+ population. A 12-year-old and a 40-year-old adult receive the identical 200 mg tablet dose once daily.
Why you might be looking for weight-based dosing
Weight-based/BSA-based dosing does not exist yet for belumosudil, but the FDA required Kadmon/Sanofi to study it as a post-marketing requirement at the time of approval:
"Conduct a clinical trial to determine the appropriate dose of belumosudil and to assess the safety, efficacy, and pharmacokinetics of belumosudil in pediatric patients with chronic graft-versus-host disease. Include at least 20 adolescents 12 to <17 years old, 4 children 2 to <12 years old, and 2 infants ≥3 months to <2 years old."
This is exactly what the ongoing trial NCT07116031 ("A Study of Belumosudil in Children," ages 1 to <18 years, Phase 1 cohort for 1 to <12 years) is designed to establish. Once completed, it is likely to define a weight-tiered or BSA-based dosing schedule for children under 12, since a flat 200 mg adult dose would be inappropriate for a young child or infant. That data is not yet available or approved.
Bottom line
- Age 12 and up: fixed 200 mg once daily (or 200 mg twice daily with strong CYP3A inducers/PPIs) - not weight-adjusted.
- Under 12: no approved dose of any kind exists yet - weight-based dosing is being actively studied but hasn't been established or published in labeling.
If you're asking because a specific child's dose was calculated by weight, that would be an off-label/investigational protocol (e.g., through the clinical trial or an individualized compassionate-use plan), not standard FDA-approved dosing - worth confirming directly with the prescribing transplant/oncology team on what protocol they're following.
Find recent pediatric trial data on Rezurock dosing in children 100mg od
Searching PubMed
belumosudil pediatric pharmacokinetics dose children
Searching the Web
belumosudil 100 mg once daily pediatric dose trial children weight
Searching the Web
Rezurock pediatric clinical trial results 2026 dosing children under 12
Reading Web Page
https://www.sciencedirect.com/science/article/pii/S000649712…
Searching the Web
"belumosudil" real-world pediatric "100 mg" "kg" dose weight tiers ASH abstract
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC11971124
Recent Pediatric Data on Belumosudil (Rezurock) Dosing - Including 100 mg OD
There is no FDA-approved weight-based dosing for belumosudil, but recent real-world/case-series data (2024-2026) show clinicians are using weight-tiered dosing off-label in children under 12, and this is likely where the "100 mg od" figure comes from.
Weight-tiered dosing used in a multi-institutional real-world study (2025-2026, presented in Blood/ASH abstract)
For patients under 12 years old, investigators used a body-weight-stratified regimen:
| Body weight | Belumosudil dose |
|---|---|
| ≥24 kg | 200 mg/day |
| 15-24 kg | 100 mg/day |
| ≤15 kg | 50 mg/day |
This is the source of the "100 mg od" dose you're asking about - it corresponds to the 15-24 kg weight tier in children too small for a full adult 200 mg dose. This dosing scheme is investigational/real-world practice, not an FDA-labeled regimen.
EHA 2026 case series (N=49, presented by Lipeng Liu, Stockholm, June 2026)
A larger pediatric case series of steroid-refractory cGVHD patients reported:
- Best overall response rate (ORR): 81.6%, with complete response in 38.7%
- Median time to response: 6 weeks (range 2-16)
- 24-week duration of response: 74.1%
- Organ-specific ORRs: GI tract 94.9%, skin 93.1%, liver 90.9%, mouth 90.0%, eyes 87.5%, lung 64.3%
- Failure-free survival 77.0%, overall survival 100%, no treatment-related discontinuations or deaths
Exact dosing tiers by weight weren't fully detailed in the public summary I could access, but this reinforces that belumosudil is being used successfully in pediatric populations below the labeled age cutoff, typically with weight-adjusted doses.
Case series from China (Chen et al., 2024, PMC11971124)
Three patients, all age 12 (at the labeled cutoff) but with low body weight, were treated at the standard 200 mg once daily adult dose (not weight-reduced), and tolerated it well over 4-7 months of follow-up, with one patient later stepped down to 200 mg every other day (qod) for maintenance. This case series specifically noted:
- Body weights were lower than those studied in the pivotal adult trials
- All three patients tolerated 200 mg daily despite low weight, without dose-limiting toxicity
- Authors flagged that PK/PD in low-weight children may differ from adults, and called for dedicated pediatric dosing studies
Context: why this matters
- On-label: Rezurock is fixed-dose 200 mg once daily for ages 12+, not weight-adjusted, per FDA labeling - population PK data showed body weight had no clinically meaningful effect on drug exposure in the 12+ population studied.
- Under 12: no approved dose exists. The 100 mg od figure appearing in recent literature reflects off-label, weight-tiered dosing (100 mg/day for 15-24 kg body weight) used in real-world pediatric case series, not a formal FDA or manufacturer-sanctioned regimen.
- The ongoing prospective trial (NCT07116031, ages 1 to <18, with a Phase 1 arm for 1 to <12 years) is intended to formally establish PK-based dosing for this younger population - results aren't yet published.
Bottom line
"100 mg od" in children reflects an off-label weight-based tier (15-24 kg) used in real-world/retrospective pediatric belumosudil series, not an approved dose. Current evidence is limited to small case series and one multi-institutional real-world cohort; formal pediatric PK trial data to support a validated dosing algorithm for children under 12 is still pending from NCT07116031.
I'd flag a recency caveat: some of these sources (EHA 2026, ASH abstract) are conference abstracts rather than peer-reviewed full papers, so dosing details may still be refined once full manuscripts are published. If you're managing an actual pediatric patient, treat these figures as descriptive of current practice patterns rather than an established standard, and coordinate dosing decisions with a pediatric BMT/GVHD specialist.
Find recent pediatric trial data on Rezurock dosing in children 100mg od
Searching the Web
belumosudil pediatric dosing trial 100 mg update 2026
Searching PubMed
belumosudil pediatric dose weight children
No new updates beyond what I already found. Confirming the same picture from current data (as of Aug 2026):
Recent Pediatric Data on Belumosudil (Rezurock) Dosing — Including the "100 mg OD" Figure
There is still no FDA-approved weight-based dosing for children. The 100 mg once-daily dose you're seeing referenced comes from off-label, real-world weight-tiered dosing used in recent pediatric case series, not from a labeled regimen.
Weight-tiered dosing reported in a multi-institutional real-world study (Blood/ASH abstract, 2025-2026)
For children under 12 years, investigators used:
| Body weight | Belumosudil dose |
|---|---|
| ≥24 kg | 200 mg/day |
| 15-24 kg | 100 mg/day |
| ≤15 kg | 50 mg/day |
The 100 mg dose corresponds specifically to the 15-24 kg weight band.
Supporting case series (peer-reviewed, PMID: 39661130, Annals of Hematology, 2025)
Chen et al. described three pediatric patients, all age 12 (the labeled cutoff), with low body weight, treated at the standard 200 mg once daily adult dose despite their small size, tolerating it well over 4-7 months. One case was later stepped down to 200 mg every other day for maintenance. The authors explicitly flagged that PK/PD may differ in low-weight children and called for dedicated pediatric dosing studies rather than extrapolating the adult fixed dose downward.
EHA 2026 case series (N=49, Lipeng Liu, June 2026)
Reported strong efficacy in steroid-refractory pediatric cGVHD (ORR 81.6%, CR 38.7%, 24-week duration of response 74.1%, no treatment-related deaths), reinforcing use in pediatric patients but without a granular published weight-dosing table in the summary available.
Status of formal trials
The prospective pediatric PK/dosing trial (NCT07116031, ages 1 to <18, with a Phase 1 arm for 1 to <12 years) that will formally define an approved weight-based algorithm is still ongoing — no published results yet as of today (Aug 18, 2026).
Bottom line
"100 mg od" reflects the 15-24 kg dosing tier used off-label/investigationally in real-world pediatric belumosudil series, not an FDA- or manufacturer-approved dose. For children ≥12 years within the approved population, evidence still supports the fixed 200 mg once-daily adult dose (tolerated even in lower-weight 12-year-olds). Formal pediatric dosing guidance for children under 12 awaits results from NCT07116031. Any use in this age group should be through a clinical trial or individualized specialist-directed protocol.
can We give 100mg
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
This is a shared conversation. Sign in to Orris to start your own chat.